# 21 U.S.C. 356 Expedited approval of drugs for serious or life-threatening diseases or conditions

21 U.S.C. 356 Expedited approval of drugs for serious or life-threatening diseases or conditions, “Expedited approval of drugs for serious or life-threatening diseases or conditions”, is a U.S. Code section of [Part A—Drugs and Devices](https://ontology.bommaritollc.com/id/01a0f06c-cb97-754b-b68a-a66a473f5a0d); in force.

IRI: <https://ontology.bommaritollc.com/id/01a0f06c-cce5-749b-bd0a-9561cfcbbfe8>

Within: [Title 21—Food and Drugs](https://ontology.bommaritollc.com/id/01a0f06c-cb65-7672-8fda-c39517ff08c0) › [Chapter 9—Federal Food, Drug, and Cosmetic Act](https://ontology.bommaritollc.com/id/01a0f06c-cb91-72e0-858b-060e8c845f23) › [Subchapter V—Drugs and Devices](https://ontology.bommaritollc.com/id/01a0f06c-cb96-7040-b454-c8f18e0e95cb) › [Part A—Drugs and Devices](https://ontology.bommaritollc.com/id/01a0f06c-cb97-754b-b68a-a66a473f5a0d)

Type: [schema:Legislation](https://schema.org/Legislation)

- `adms:identifier`: [usc-section 21 U.S.C. 356](https://ontology.bommaritollc.com/id/01a0f06c-cce6-751b-88e5-d7a39b654a20)
- `eli:cites`:
  - [21 U.S.C. 353 Exemptions and consideration for certain drugs, devices, and biological products](https://ontology.bommaritollc.com/id/01a0f06c-cccb-7545-90e2-a1651be32192)
  - [21 U.S.C. 355 New drugs](https://ontology.bommaritollc.com/id/01a0f06c-ccd6-7038-b7ea-5f9e1b3b3f50)
  - [21 U.S.C. 355f Extension of exclusivity period for new qualified infectious disease products](https://ontology.bommaritollc.com/id/01a0f06c-cce1-7368-a538-a6e455da9969)
  - [21 U.S.C. 379h Authority to assess and use drug fees](https://ontology.bommaritollc.com/id/01a0f06c-cd9d-7067-a1f7-38b3a2d65388)
  - [Subchapter I—Administration and Miscellaneous Provisions](https://ontology.bommaritollc.com/id/01a0f07c-d2a8-71a0-898c-d3e3cf9ebb25)
  - [42 U.S.C. 247d Public health emergencies](https://ontology.bommaritollc.com/id/01a0f07c-d961-7148-9e7e-f0bbd971a175)
  - [42 U.S.C. 262 Regulation of biological products](https://ontology.bommaritollc.com/id/01a0f07c-d9ca-7203-a1d8-2d79c0329140)
  - [42 U.S.C. 264 Regulations to control communicable diseases](https://ontology.bommaritollc.com/id/01a0f07c-da01-7612-a2fd-2f3800f7d8af)
  - [21 CFR Part 1271—Human cells, tissues, and cellular and tissue-based products](https://ontology.bommaritollc.com/id/01a0f094-b8c4-72af-b6b8-32db4b011f3d)
  - [21 CFR 201.57 Specific requirements on content and format of labeling for human prescription drug and biological products described in § 201.56(b)(1).](https://ontology.bommaritollc.com/id/01a0f094-c333-77df-9523-a7dc0b2a5cb0)
- `prov:wasDerivedFrom`:
  - [evidence from https://www.govinfo.gov/app/details/USCODE-2024-title21/USCODE-2024-title21-chap9-subchapV-partA-sec356](https://ontology.bommaritollc.com/id/01a0f06c-cce5-749b-bd0a-95601968fc27)
  - [evidence from https://www.govinfo.gov/app/details/](https://ontology.bommaritollc.com/id/01a0f06c-d151-77f3-9ea7-1992b628f43c)
  - [evidence from https://www.govinfo.gov/app/details/](https://ontology.bommaritollc.com/id/01a0f0d2-2d46-7595-b2a1-8202e2e0adf9)
  - [evidence from https://www.govinfo.gov/link/uscode/21/356?type=usc&year=mostrecent&link-type=details](https://ontology.bommaritollc.com/id/01a10f15-fe24-7123-8817-0c50a0d625b9)
- `schema:isPartOf`: [Part A—Drugs and Devices](https://ontology.bommaritollc.com/id/01a0f06c-cb97-754b-b68a-a66a473f5a0d)
- `schema:legislationIdentifier`: 21 U.S.C. 356
- `schema:legislationJurisdiction`: [United States](https://ontology.bommaritollc.com/id/01a0ed8e-f797-7004-b7f5-bec2695977c0)
- `schema:legislationLegalForce`: [schema:InForce](https://schema.org/InForce)
- `schema:legislationType`: [U.S. Code section](https://ontology.bommaritollc.com/vocab/leg/uscSection)
- `schema:name`: Expedited approval of drugs for serious or life-threatening diseases or conditions
- `schema:url`: [https://www.govinfo.gov/link/uscode/21/356?type=usc&year=mostrecent&link-type=details](https://www.govinfo.gov/link/uscode/21/356?type=usc&year=mostrecent&link-type=details)
- `skos:prefLabel`: 21 U.S.C. 356 Expedited approval of drugs for serious or life-threatening diseases or conditions

## Elsewhere

- [Official page](https://www.govinfo.gov/link/uscode/21/356?type=usc&year=mostrecent&link-type=details) (www.govinfo.gov)
- [Source](https://www.govinfo.gov/app/details/USCODE-2024-title21/USCODE-2024-title21-chap9-subchapV-partA-sec356) (www.govinfo.gov)
- [Source](https://www.govinfo.gov/app/details/) (www.govinfo.gov)

## Pointing here

- Cited by (12; `eli:cites`):
  - [21 U.S.C. 331 Prohibited acts](https://ontology.bommaritollc.com/id/01a0f06c-cc92-7163-972f-ca345be44724)
  - [21 U.S.C. 355 New drugs](https://ontology.bommaritollc.com/id/01a0f06c-ccd6-7038-b7ea-5f9e1b3b3f50)
  - [21 U.S.C. 356-1 Accelerated approval of priority countermeasures](https://ontology.bommaritollc.com/id/01a0f06c-cce6-751b-88e5-d7a5b6b36a00)
  - [21 U.S.C. 356-2 Accelerated approval Council](https://ontology.bommaritollc.com/id/01a0f06c-cce7-77f5-973c-c21eb38a07c9)
  - [21 U.S.C. 356b Reports of postmarketing studies](https://ontology.bommaritollc.com/id/01a0f06c-ccea-769f-b60a-251047e97ffa)
  - [21 U.S.C. 356g Standards for regenerative medicine and regenerative advanced therapies](https://ontology.bommaritollc.com/id/01a0f06c-ccf1-73bd-b8f7-c59829a2609a)
  - [21 U.S.C. 357 Qualification of drug development tools](https://ontology.bommaritollc.com/id/01a0f06c-ccf8-74ee-81de-0c7ba67cef11)
  - [21 U.S.C. 360bbb-0 Expanded access policy required for investigational drugs](https://ontology.bommaritollc.com/id/01a0f06c-cd39-74a5-b7bd-94789cf233c0)
  - [21 U.S.C. 360bbb-3c Expedited development and review of medical products for emergency uses](https://ontology.bommaritollc.com/id/01a0f06c-cd42-7180-a20f-e2d054a3a620)
  - [21 U.S.C. 360ff Priority review to encourage treatments for rare pediatric diseases](https://ontology.bommaritollc.com/id/01a0f06c-cd25-70dc-81b8-fa28ceb7a6e8)
  - [21 U.S.C. 387r Drug products used to treat tobacco dependence](https://ontology.bommaritollc.com/id/01a0f06c-ce20-77e6-9908-414b70d27f6b)
  - [42 U.S.C. 247d-5 Combating antimicrobial resistance](https://ontology.bommaritollc.com/id/01a0f07c-d96a-7307-881e-0f6020659fba)
- Amended by (3; `eli:amends`):
  - [Pub. L. 112-144](https://ontology.bommaritollc.com/id/01a0f06a-a3b6-70e5-8204-79bb2755f506)
  - [Pub. L. 114-255](https://ontology.bommaritollc.com/id/01a0ee1d-96d5-7151-84b6-b5e19f0e00ec)
  - [Pub. L. 117-328](https://ontology.bommaritollc.com/id/01a0edf4-a3b3-73ad-8a5b-366dfc33cea1)
- Rules made under it (3; `eli:based_on`):
  - [21 CFR Part 208—Medication Guides for prescription drug products](https://ontology.bommaritollc.com/id/01a0f094-b83d-715a-a06f-19ec5ee04f89)
  - [21 CFR Part 230—Certification and postmarketing reporting for designated medical gases (Eff. 12-18-25)](https://ontology.bommaritollc.com/id/01a0f094-b846-700a-99cf-b5ff460516cd)
  - [21 CFR Part 314—Applications for FDA approval to market a new drug](https://ontology.bommaritollc.com/id/01a0f094-b84d-7031-b149-cb632d656858)
- Its changes, from (1; `eli:changes`):
  - [Pub. L. 105-115](https://ontology.bommaritollc.com/id/01a0f06c-d29f-7443-a96a-3934363a8187)

---
Also as: [Turtle](https://ontology.bommaritollc.com/id/01a0f06c-cce5-749b-bd0a-9561cfcbbfe8.ttl), [JSON-LD](https://ontology.bommaritollc.com/id/01a0f06c-cce5-749b-bd0a-9561cfcbbfe8.jsonld), [N-Triples](https://ontology.bommaritollc.com/id/01a0f06c-cce5-749b-bd0a-9561cfcbbfe8.nt), [HTML](https://ontology.bommaritollc.com/id/01a0f06c-cce5-749b-bd0a-9561cfcbbfe8)
Cite as: 21 U.S.C. 356 Expedited approval of drugs for serious or life-threatening diseases or conditions. bc-ontology, release 0.1.0-rc38, 2026-10-21. https://ontology.bommaritollc.com/id/01a0f06c-cce5-749b-bd0a-9561cfcbbfe8
Release 0.1.0-rc38, graph hash 05350a11cf9d0c42fba51e92b877115781ab65cb92afcd6b172ff9f8f4abf0bd.
